Skip to Main Content

INFORMATION FOR

    Josh Saskin

    he/him/his
    DownloadHi-Res Photo

    About

    Biography

    Josh is a third-year MD-PhD student from Newtown, PA. He is currently a student in the lab of Sidi Chen, where he his graduate work lies within the intersection of cancer immunology, genetic engineering, and systems biology.

    Josh completed his undergraduate education at Brown University, where he earned degrees in Chemistry and Biomedical Engineering with honors. At Brown, Josh’s research dissected GPCR-mediated signaling pathways implicated in melanoma progression. He also contributed to a thorough functional characterization of regulatory SNPs that yields insight into the evolutionary mechanisms of human skin color diversity. At Yale, Josh hopes to leverage his background in cell biology and functional genomics to explore how gene editing and high throughput screening can be used to identify therapies for hematologic and solid malignancies.

    Outside of science and medicine, Josh enjoys pottery, cooking, and walking dogs around New Haven.

    Last Updated on June 27, 2025.

    Departments & Organizations

    Education & Training

    ScB
    Brown University, Chemistry (2023)
    ScB
    Brown University, Biomedical Engineering (2023)

    Research

    Research at a Glance

    Yale Co-Authors

    Frequent collaborators of Josh Saskin's published research.

    Publications

    Featured Publications

    • OR7A10 GPCR engineering boosts CAR-NK therapy against solid tumours
      Yang L, Renauer P, Tang K, Saskin J, Zhou L, Zou C, Lee S, Fox M, Johnson-Noya S, Weiss B, Deng S, Fang P, Chen B, Sferruzza G, Fooladi S, Zhao K, Park D, Zhang F, Tu J, Chen J, Moliterno J, Gunel M, Peng L, Chen S. OR7A10 GPCR engineering boosts CAR-NK therapy against solid tumours. Nature 2026, 652: 740-751. PMID: 41741641, DOI: 10.1038/s41586-026-10149-8.
      Peer-Reviewed Original Research
      This study investigates OR7A10-engineered CAR-NK cells, showing they enhance tumor-killing ability, persistence, and survival in solid tumor models, offering a scalable cancer therapy.

    2025

    2024

    Get In Touch

    Contacts

    Events

    Sep 202628Monday